Lipella Pharmaceuticals INC.
SEC CIK 1347242 · LIPO · last insider filing 2025-04-07
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Kaufman Jonathan H | Director · See remarks below. | filed 2022 - 2025 |
| Kim Byong | Director | filed 2022 - 2024 |
| Pruchnic Ryan | Director | filed 2022 - 2024 |
| Chancellor Michael B | Director · Chief Medical Officer | filed 2022 - 2024 |
| Yoshimura Naoki | Director | filed 2023 - 2024 |
| Cohen Daniel R | Director | filed 2023 - 2024 |
| Birder Lori | Director | filed 2023 - 2024 |
| Battleman David S. | Director | filed 2023 - 2023 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Johnston Douglas | Chief Financial Officer | filed 2022 - 2024 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.